Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Retained Earnings (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Retained Earnings data on record, last reported at -$1.1 million in Q1 2025.

  • For Q1 2025, Retained Earnings rose 95.65% year-over-year to -$1.1 million; the TTM value through Mar 2025 reached -$1.1 million, up 95.65%, while the annual FY2025 figure was -$1.1 million, 95.65% up from the prior year.
  • Retained Earnings reached -$1.1 million in Q1 2025 per SXTC's latest filing, up from -$24.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $956142.0 in Q1 2022 and bottomed at -$24.7 million in Q1 2024.
  • Average Retained Earnings over 5 years is -$7.0 million, with a median of -$1.1 million recorded in 2025.
  • Peak YoY movement for Retained Earnings: surged 109.61% in 2022, then plummeted 12407.74% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$10.0 million in 2021, then soared by 109.61% to $956142.0 in 2022, then crashed by 120.66% to -$197571.0 in 2023, then tumbled by 12407.74% to -$24.7 million in 2024, then soared by 95.65% to -$1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$1.1 million in Q1 2025, -$24.7 million in Q1 2024, and -$197571.0 in Q1 2023.